US20070087010A1 - Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders - Google Patents
Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders Download PDFInfo
- Publication number
- US20070087010A1 US20070087010A1 US11/583,986 US58398606A US2007087010A1 US 20070087010 A1 US20070087010 A1 US 20070087010A1 US 58398606 A US58398606 A US 58398606A US 2007087010 A1 US2007087010 A1 US 2007087010A1
- Authority
- US
- United States
- Prior art keywords
- cells
- apoptotic
- patient
- bodies
- apoptotic bodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001640 apoptogenic effect Effects 0.000 title claims abstract description 111
- 238000011282 treatment Methods 0.000 title claims abstract description 35
- 230000000626 neurodegenerative effect Effects 0.000 title claims abstract description 17
- 208000012902 Nervous system disease Diseases 0.000 title description 13
- 208000025966 Neurological disease Diseases 0.000 title description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 127
- 238000011321 prophylaxis Methods 0.000 claims abstract description 15
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 6
- 230000000926 neurological effect Effects 0.000 claims abstract description 5
- 210000000601 blood cell Anatomy 0.000 claims abstract 5
- 238000000034 method Methods 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 18
- 230000001413 cellular effect Effects 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 230000002757 inflammatory effect Effects 0.000 claims description 12
- 201000010374 Down Syndrome Diseases 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 206010044688 Trisomy 21 Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 206010039966 Senile dementia Diseases 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 208000016192 Demyelinating disease Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000012659 Joint disease Diseases 0.000 claims description 3
- 206010028372 Muscular weakness Diseases 0.000 claims description 3
- 206010036105 Polyneuropathy Diseases 0.000 claims description 3
- 208000029033 Spinal Cord disease Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 210000004748 cultured cell Anatomy 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 201000005518 mononeuropathy Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000036473 myasthenia Effects 0.000 claims description 3
- 208000013315 neuromuscular junction disease Diseases 0.000 claims description 3
- 230000002981 neuropathic effect Effects 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 208000027232 peripheral nervous system disease Diseases 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 230000007824 polyneuropathy Effects 0.000 claims description 3
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims description 2
- 239000006194 liquid suspension Substances 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 abstract description 33
- 230000001338 necrotic effect Effects 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000027928 long-term synaptic potentiation Effects 0.000 description 8
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 6
- 210000001320 hippocampus Anatomy 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 208000010247 contact dermatitis Diseases 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 102000011727 Caspases Human genes 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 2
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 2
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- -1 permanganates Chemical class 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000003956 synaptic plasticity Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- JXSSPZOCHGZWJP-UHFFFAOYSA-N 1,2-difluoro-3,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(F)=C1[N+]([O-])=O JXSSPZOCHGZWJP-UHFFFAOYSA-N 0.000 description 1
- 108050005848 Annexin A10 Proteins 0.000 description 1
- 102100028117 Annexin A10 Human genes 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 102400000730 Canstatin Human genes 0.000 description 1
- 101800000626 Canstatin Proteins 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 102000004046 Caspase-2 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical group O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 230000009925 apoptotic mechanism Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- XVLXYDXJEKLXHN-UHFFFAOYSA-M dioc6 Chemical compound [I-].O1C2=CC=CC=C2[N+](CCCCCC)=C1C=CC=C1N(CCCCCC)C2=CC=CC=C2O1 XVLXYDXJEKLXHN-UHFFFAOYSA-M 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000006122 isoprenylation Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000001121 vomeronasal organ Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46432—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Definitions
- This invention relates to biochemical and biological compositions and to the uses thereof in the treatment and/or prophylaxis of various neurodegenerative and other neurological disorders in mammalian patients. More particularly, it relates to treatment and prophylaxis of neurodegenerative and other neurological disorders by administration of compositions containing the mammalian cellular materials and fragments thereof, and to the compositions containing the mammalian cellular materials and fragments themselves, and to processes for preparing such compositions.
- Apoptosis is the process of programmed cell death, described by Kerr et al in 1992 [Kerr J F R, Wyllie A H, Currie A R (1992). “Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. “ British Journal of Cancer 26: 239-257”], by which steady-state levels of the various organ systems and tissues in the body are maintained as continuous cell division and differentiation takes place.
- apoptotic cells may break up into a number of small fragments known as apoptotic bodies, consisting essentially of membrane-bound bodies containing intact organelles, chromatin, etc. Apoptotic bodies are normally rapidly removed from the body by phagocytosis by macrophages, dendritic cells and other antigen presenting cells, before they can become lysed and release their potentially pro-inflammatory intracellular contents.
- apoptosis is thought to proceed as follows. Three phases can be identified in the apoptotic mechanism of programmed cell death:
- the induction phase is dependent, in part, on specific interactions of death-inducing signals at the cell surface membrane.
- One common signal is initiated by the binding of specific ligands to receptors of the TNF receptor family present on the cell membrane.
- One important such receptor is Fas (APO-1, CD95), which interacts with Fas-ligand to initiate apoptosis.
- the effector phase activated by the binding of receptors and ligands of the induction phase, leads to the activation of caspases, cystinyl-aspartate-requiring proteinases (proteolytic enzymes), including caspases 1 and 8.
- This activation may be associated with a change in the permeability of mitochondria, allowing the release of cytochrome-c which is involved in caspase activation.
- Activated caspases initiate a chain of lethal proteolytic events culminating in the changes in chromatin and cytoskeletal components seen in apoptosis.
- In situ labelling of nuclear DNA fragmentation for example, using commercially available terminal dUTP nick end labelling (TUNEL) assays, are an alternative and more reproducible measure for the determination of fragmented DNA in apoptotic cells and cells undergoing apoptosis [Gavrieli Y, Sherman Y, Ben-Sasson S A (1992)”, Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation”. Journal of Cell Biology 119: 493-501].
- TUNEL terminal dUTP nick end labelling
- phosphatidylserine becomes exposed externally on the cell membrane [Fadok V A, Voelker D R, Campbell P A, Cohen J J, Bratton D L, Henson P M (1992), “Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages”.
- phosphatidylserine binds to specific receptors to mediate the uptake and clearance of apoptotic cells in mammals [Fadok V A, Bratton D L, Rose D M, Pearson A, Ezekewitz R A B, Henson P M (2000), “A receptor for phosphatidylserine-specific clearance of apoptotic cells”, Nature 405: 85-90].
- the surface expression of phosphatidylserine on cells is another recognised method of identification of apoptotic cells.
- necrotic cells in contrast, is cell death of a pathological nature, resulting from injury, bacterial toxin effects, inflammatory mediators, etc., and involving membrane rupture and release of intracellular contents to the surrounding tissue, often with harmful inflammatory consequences. Accordingly, one of the ways in which necrotic cells may be detected and characterized is by detection of compromised cell membranes, e.g. by methods of staining with propidium iodide followed by flow cytometry or microscopy.
- This invention is directed, in part, to the novel and unexpected discovery that administration to a mammal of apoptotic cells and/or apoptotic bodies previously prepared ex vivo, can be used in the prophylaxis and/or treatment of neurodegenerative and/or other neurological disorders in the treated mammal.
- this invention is directed to a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable excipient and an effective amount of apoptotic cells and/or apoptotic bodies.
- compositions preferably employ an aqueous based pharmaceutically acceptable excipient although other excipients can be used.
- this invention is directed to a method for the treatment of or prophylaxis against neurodegenerative and other neurological medical disorders in a mammalian patierit, which comprises administering to the patient an effective amount of apoptotic bodies and/or apoptotic cells.
- compositions described herein are preferably accomplished by administering to the patient the pharmaceutical compositions described herein.
- the FIGURE is a graph showing a comparison of net ear swelling in mice treated with the compositions of this invention and a control group.
- This invention is directed to the treatment and/or prophylaxis of neurodegenerative and/or other neurological disorders by the administration of apoptotic cells and/or bodies.
- Neurodegenerative disorders including Down's syndrome, Alzheimer's disease and Parkinson's disease, are associated with increased levels of reactive oxygen species (ROS), certain inflammatory cytokines, including interleukin-1 ⁇ (IL-1 ⁇ ) [see Griffin W S T, Stanley L C, Ling C, White L, Macleod V. Perrot L J, White C L, Araoz C (1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down's syndrome and Alzheimer disease. Proceedings of the National Academy of Sciences USA 867611-7615; Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996).
- ROS reactive oxygen species
- IL-1 ⁇ interleukin-1 ⁇
- Interleukin (IL)-1 beta, IL-1, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neuroscience Letters 211:13-16]. It has also been shown that IL-1 ⁇ inhibits long-term potentiation in the hippocampus [Murray C A, Lynch M A (1998). Evidence that increase hippocampal expression of the cytokine interleukin-1 ⁇ is a common trigger for age and stress-induced impairments in long-term potentiation. Journal of Neuroscience 18:2974-2981].
- Neurodegenerative and other neurological disorders treatable by the present invention include Down's syndrome, Alzheimer's disease, Parkinson's disease, senile dementia, depression and the like. In summary, it can be substantially any neurodegenerative or other neurological disorder.
- Apoptotic cells and “apoptotic bodies,” as the terms are used herein, means cells and cell bodies which exhibit one or more of the following apoptosis-characterizing features: surface exposure of phosphatidylserine, as detected by standard, accepted methods of detection such as Annexin V staining; alterations in mitochondrial membrane permeability measured by standard, accepted methods (e.g. Salvioli, S., Ardizzoni, A., Franceschi, C. Cossarizza, A.
- the apoptotic cells and/or apoptotic bodies for use in the present invention preferably comprise not more than about 35 weight percent of necrotic cells and/or necrotic bodies based on the total weight of the apoptotic cells/bodies and necrotic cells/bodies; more preferably, not more than about 20 weight percent; and even more preferably, not more than about 10 weight percent. At these levels, the presence of such necrotic cells and/or bodies are believed not to significantly alter in vivo processes. In its most preferred embodiment, the apoptotic cells/bodies are substantially free of necrotic cells and or bodies (i.e., less than about 2 weight percent of necrotic cells/bodies).
- the apoptotic cells and/or apoptotic bodies for use in the present invention are prepared ex vivo from mammalian cells that are compatible with those of the mammalian patient. They can be prepared from substantially any type of mammalian cell including cultured cell lines. Preferably they are prepared from a cell type derived from the mammalian patient's own body or from an established cell line. More preferably they are prepared from white blood cells of blood compatible with that of the mammalian patient, more preferably from the patient's own white blood cell and even more preferably from the patient's own T lymphocytes. Even more preferably they are prepared from an established cell line.
- the apoptotic cells and/or apoptotic bodies are prepared extracorporeally prior to administration to the patient. Thus, in one embodiment, an aliquot of the patient's blood may be withdrawn, e.g. by venipuncture, and at least a portion of the white cells thereof subjected extracorporeally to apoptosis inducing
- a variety of methods of inducing apoptosis in mammalian cells, so as to create apoptotic cells and apoptotic bodies, are known in the art and essentially any of these can be adopted in preparing apoptotic bodies for use in the present invention.
- One such method is the subjection of the cells to ionizing radiation ( ⁇ -rays, x-rays, etc.) and/or non-ionizing electromagnetic radiation including ultraviolet light.
- Apoptosis can be induced by subjecting cells to ultrasound.
- Another method is the treatment of the cells with drugs such as non-specific protein kinase inhibitors as exemplified by staurosporine (see Bombeli, Karsan, Tait and Hirlan, (1997) “Apoptotic Vascular Endothelial Cells Become Procoagulant”, Blood , Vol. 89:2429-2442).
- drugs such as non-specific protein kinase inhibitors as exemplified by staurosporine (see Bombeli, Karsan, Tait and Hirlan, (1997) “Apoptotic Vascular Endothelial Cells Become Procoagulant”, Blood , Vol. 89:2429-2442).
- chemotherapeutic agents used for the treatment of malignant tumours induce apoptosis, for example adriamycin, as can statin drugs (3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors) [Guijarro C, Blanco-Colio L M, Ortego M, Alonso C, Ortiz A, Plaza J J, Diaz C, Hernandez G, Edigo J (1998), “3-hydroxy-3methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle in culture,“ Circulation Research 83: 490-500] and colcicine [Suzuki Y (1998)”, “Cell death, phagocytosis and neurogenesis in mouse olfactory epithelium and vomeronasal organ after colcicine treatment,” Annals of the New York Academy of Sciences 855: 252-254].
- statin drugs 3-hydroxy-3methylglutaryl coenzyme A reductase
- oxidative stress is the application of oxidative stress to cells extracorporeally (see for example Buttke and Sandstrom (1994) “Oxidative Stress as a Mediator of Apoptosis,” Immunology Today , Vol. 15:7-10).
- This can be achieved by treating the cells, in suspension, with chemical oxidizing agents such as hydrogen peroxide, other peroxides and hydroperoxides, ozone, permanganates, periodates, and the like.
- Biologically acceptable such oxidizing agents are preferably used, so as to reduce potential problems associated with residues and contaminations of the apoptotic cells and apoptotic bodies so formed.
- the present invention is not restricted to any particular method of producing apoptotic cells and apoptotic bodies, for use herein, and any suitable, known process can be used.
- Methods for the detection and quantitation of apoptosis can be used to determine the presence and level of apoptosis in the preparation to be administered to the patient in the present invention. At least one of the methods from those described in the introduction above should be used to confirm the level of apoptosis achieved prior to administration. They are suitably purified prior to use, by methods known in the art, such as differential centrifugation.
- apoptotic cells and/or apoptotic bodies care should be taken not to apply excessive levels of oxidative stress, radiation, drug treatment, etc., since otherwise there is a significant risk of causing necrosis of at least some of the cells under treatment. Necrosis causes cell membrane rupture and the release of cellular contents often with biologically harmful results, particularly inflammatory events, so that the presence of necrotic cells and their components along with the apoptotic bodies is best avoided. Appropriate levels of treatment of the cells to create apoptotic bodies for use in the present invention depend to some extent on the nature of the chosen cells and cellular composition, and the type of treatment chosen to induce apoptosis. Such appropriate levels are readily determinable by those skilled in the art, having regard to the available scientific literature on the subject including the above-reference articles.
- One preferred process according to the present invention involves the culture of cells from the patient, or a compatible mammalian cell line.
- the cultured cells may then be treated to induce apoptosis and to create apoptotic cells and/or apoptotic bodies therein.
- the cells, suspended in the patient's plasma or another suitable suspension medium, such as saline or a balanced mammalian cell culture medium, can then be administered as indicated below.
- the numbers of apoptotic cells and/or bodies can be determined by published methods available in the scientific literature on the subject including the above-reference articles.
- apoptotic cells and/or apoptotic bodies required for administration to the patient to obtain the required clinical benefit will vary depending on the source of cells, the patient's condition, the age and weight of the patient and other relevant factors which are readily determinable by the attending clinician.
- an example of a preferred process according to the present invention accordingly involves extraction of an aliquot of blood from the patient to be treated, separation of the white cells therefrom, and treatment of the white cells under apoptosis-causing conditions, so as to create a cellular composition in which significant numbers of the white cells therein have been apoptosed so as to create therein substantial numbers of apoptotic cells or bodies. Then the treated composition is administered to the patient. More preferably, T lymphocytes, isolated from the blood by known means, and suspended as above, may be used as a source of apoptotic cells and apoptotic bodies.
- the number of viable cells selected for treatment to create apoptotic cells and/or apoptotic bodies is suitably up to about 4 ⁇ 10 9 , preferably from about 1,000,000 to about 1,000,000,000 and most preferably from about 50,000,000 to about 150,000,000, for each administration to a human patient. From about 10% to 90%, preferably from about 30% to 70% of the cellular composition for administration is comprised of apoptotic bodies and/or apoptotic cells, the balance being viable cells and necrotic cells. Accordingly, the preferred amounts of apoptotic cells and/or apoptotic bodies for administration are those produced by subjecting these numbers of cells to the apoptosing conditions.
- these numbers of white cells are obtainable in blood aliquots of volume up to about 400 ml, preferably up to 100 ml. More specifically, 50,000,000-150,000,000 cells is equivalent to the white cells in blood aliquots of volume 10 -30 ml.
- the volume of the aliquot of blood withdrawn from the patient for treatment to create apoptotic cells and/or apoptotic bodies therein is suitable up to about 400 ml, preferably from about 0.1 to about 100 ml and most preferably from about 5 to about 15 ml. Accordingly, the preferred amounts of apoptotic cells and/or apoptotic bodies for administration are those corresponding to the numbers derivable from the white blood cells, or isolated T lymphocytes, contained in such quantities of whole blood, following subjection to apoptosis-inducing conditions.
- the suspension of treated apoptotic cells and/or bodies for administration to the patient is prepared in a biologically acceptable liquid suspending medium, such as the patient's serum or plasma, saline or balanced mammalian cell culture medium.
- a biologically acceptable liquid suspending medium such as the patient's serum or plasma, saline or balanced mammalian cell culture medium.
- the addition of other factors, such as cytokines, hormones, products of stressed cells or other appropriate biologically active material may enhance the benefit of the administered apoptotic cellular materials.
- the aliquot can be introduced into the patient's body by any suitable method, most preferably intramuscular injection but also including subcutaneous injection, mini-grafting, intra peritoneal injection, intra-arterial injection, intravenous injection and oral administration.
- the apoptotic entities can be delivered to the specific body organ and/or site by using any appropriate, known delivery system.
- compositions of this invention may optionally include a pharmaceutically acceptable excipient.
- suitable excipients include sterile water, sterile saline, phosphate buffered saline, and the like.
- the pharmaceutical compositions comprise an effective amount of apoptotic bodies/cells to induce a suitable prophylactic and/or therapeutic response in the patient at risk of suffering or suffering from a neurodegenerative disease.
- the composition administered to the mammalian patient comprises from about 10,000 to 10,000,000 apoptotic cells or bodies per kilogram of body weight, more preferably from about 500,000 to 5,000,000 and most preferably from about 1,500,000 to about 4,000,000 apoptotic cells and/or bodies per kg body weight.
- the specific dose employed will, of course, be dependent upon the age, weight and severity of the disease in the treated patient all of which are within the skill of the attending clinician.
- the patient may be given a course of treatments with apoptotic cells and/or bodies according to the invention.
- Each course of treatment may involve administration to the patient of from 1 to 6 aliquots of suspended cellular material, as described above. No more than one such aliquot should be administered per day, and the maximum rest period between any two consecutive administrations should be not greater than about 21 days.
- Booster treatments as described below may advantageously be used.
- the patient may undergo booster treatments, with a further course of administration of aliquots of suspended apoptotic cells and/or apoptotic bodies as described above, at intervals of three to four months.
- the present invention is applicable to the treatment and prophylaxis of a wide variety of mammalian neurodegenerative and other neurological disorders. These include, but are not limited to, Down's Syndrome, Alzheimer's disease, Parkinson's disease, senile dementia, depression, multiple sclerosis, Huntington's disease, peripheral neuropathies, spinal cord diseases, neuropathic joint diseases, chronic inflammatory demyelinating disease (CIPD), neuropathies including mononeuropathy, polyneuropathy, symmetrical distal sensory neruopathy, cystic fibrosis, neuromuscular junction disorders and myasthenias. In summary, it can be substantially any neurodegenerative or other neurological disorder.
- CIPD chronic inflammatory demyelinating disease
- neuropathies including mononeuropathy, polyneuropathy, symmetrical distal sensory neruopathy, cystic fibrosis, neuromuscular junction disorders and myasthenias.
- it can be substantially any neurodegenerative or other neurological disorder.
- Apoptotic bodies were prepared from murine fibroblasts.
- the murine fibroblasts were treated with 50 mM sodium butyrate in RPMI medium, at confluency for one day, and then the sodium butyrate medium was changed.
- the cells can additionally be irradiated with UV-light.(e.g. 75 mj). Supernatant containing floating cells is removed 24 hours following irradiation.
- Apoptotic bodies were quantitated by centrifuging the supernatant (1200 rpm, 5 minutes), aspirating the supernatant, washing the resulting cell pellet with PBS and centrifuging again, as above.
- the pellet containing the apoptotic bodies was re-suspended in PBS.
- the cells were stored in PBS at 4° C. for the duration of the experiment.
- the cells to be stained for quantitation were re-suspended in 1X binding buffer at a concentration of 1 ⁇ 10 6 cells/ml. 100 ⁇ l of the cells were transferred to a 5 m1 tube, and 10 ⁇ l of fluorescein-conjugated annexin V and 10 ⁇ l propidium iodide reagent was added.
- the cells were gently vortexed and the cell mixture incubated for 15 minutes at 25° C. in the dark. Following the incubation, 400 ⁇ l of 1X binding buffer is added to each tube. The sample was analyzed on a flow cytometer over one hour.
- the first, control group A received no treatment.
- the second, test group B was treated with an injection of suspended apoptotic bodies prepared as described above, 50 ⁇ l volume containing at least 150,000 bodies per injection of blood subjected to stressors as described above. Treatments, each involving intramuscular injection of 50 ⁇ l of the respective liquid, started on the day of sensitization, and were repeated every day for a total of six days. On the same day as the last treatment, but after its administration, the animals were challenged with DNFB, by applying to the right ear of each animal 10 ⁇ l of 0.2% solution of DNFB in acetone and olive oil. To the left ear of each animal was applied the acetone/olive oil solvent, without DNFB.
- Ear thickness was measured, 24 hours after challenge, with a Peacock spring-loaded micrometer (Ozaki Co., Tokyo, Japan). The results were expressed as the thickness and difference in thickness of the right ears and the left ears of each animal, at 24 hours after challenge.
- the effectiveness of the processes and compositions of the present invention in preventing and alleviating inflammation due to CHS indicates that administration of apoptotic cells and bodies as described up-regulates the in vivo generation of anti-inflammatory Th-2 derived cytokines such as IL-10 (known to be implicated in CHS—see Kondo, McKenzie and Sauder, “The Journal of Investigative Dermatology,” Vol. 103, 1994, page 811-814) and/or down-regulates Th-1 inflammatory cytokines such as TNF ⁇ and IL-6.
- Th-2 derived cytokines such as IL-10
- Th-1 inflammatory cytokines such as TNF ⁇ and IL-6.
- inflammatory cytokines are implicated in inflammation-related disorders of the brain, namely the neuroinflammatory, neurodegenerative and neurological disorders such as Alzheimer's disease, senile dementia, multiple sclerosis, depression, Down's syndrome, Huntington's disease, peripheral neuropathies, spinal cord diseases, neuropathic joint diseases, chronic inflammatory demyelinating disease (CIPD), neuropathies including mononeuropathy, polyneuropathy, symmetrical distal sensory neuropathy, cystic fibrosis, neuromuscular junction disorders, myasthenias and Parkinson's disease.
- CIPD chronic inflammatory demyelinating disease
- Neurodegenerative diseases including Down's syndrome, Alzheimer's disease and Parkinson's disease, are associated with increased levels of certain inflammatory cytokines, including interleukin-1 ⁇ (IL-1 ⁇ ) [see Griffin W S T, Stanley L C, Ling C, White L, Macleod V. Perrot L J, White C L, Araoz C (1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proceedings of the National Academy of Sciences USA 867611-7615; Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996).
- IL-1 ⁇ interleukin-1 ⁇
- Interleukin (IL)-1 beta, IL-1, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neuroscience Letters 211:13-16]. It has also been shown that IL-1 ⁇ , inhibits long-term potentiation in the hippocampus [Murray C A, Lynch M A (1998). Evidence that increase hippocampal expression of the cytokine interleukin-1 ⁇ is a common trigger for age and stress-induced impairments in long-term potentiation. Journal of Neuroscience 18:2974-2981].
Abstract
Treatment and/or prophylaxis, in mammalian patients, of neurodegenerative and other neurological medical disorders is effected by administering to the patient effective amounts of apoptotic bodies and/or apoptotic cells, preferably those derived from the patient's own white blood cells, e.g. by extracorporeal treatment of the patient's blood cells to induce apoptosis and administration of the apoptotic bodies and/or cells so formed to the patient.
Description
- This invention relates to biochemical and biological compositions and to the uses thereof in the treatment and/or prophylaxis of various neurodegenerative and other neurological disorders in mammalian patients. More particularly, it relates to treatment and prophylaxis of neurodegenerative and other neurological disorders by administration of compositions containing the mammalian cellular materials and fragments thereof, and to the compositions containing the mammalian cellular materials and fragments themselves, and to processes for preparing such compositions.
- Two mechanisms of cell death in the body are recognized, necrosis and apoptosis. Apoptosis is the process of programmed cell death, described by Kerr et al in 1992 [Kerr J F R, Wyllie A H, Currie A R (1992). “Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. “British Journal of Cancer 26: 239-257”], by which steady-state levels of the various organ systems and tissues in the body are maintained as continuous cell division and differentiation takes place. Cells undergoing apoptosis often exhibit distinctive morphological changes such as a pronounced decrease in cell volume, modification of the cytoskeletons resulting in pronounced membrane blebbing, a condensation of the chromatin, and degradation of the DNA into oligonucleosomal fragments. Following these morphological changes, an apoptotic cell may break up into a number of small fragments known as apoptotic bodies, consisting essentially of membrane-bound bodies containing intact organelles, chromatin, etc. Apoptotic bodies are normally rapidly removed from the body by phagocytosis by macrophages, dendritic cells and other antigen presenting cells, before they can become lysed and release their potentially pro-inflammatory intracellular contents.
- In simple outline, apoptosis is thought to proceed as follows. Three phases can be identified in the apoptotic mechanism of programmed cell death:
- Induction phase;
- Effector phase; and
- Degradation phase.
- The induction phase is dependent, in part, on specific interactions of death-inducing signals at the cell surface membrane. One common signal is initiated by the binding of specific ligands to receptors of the TNF receptor family present on the cell membrane. One important such receptor is Fas (APO-1, CD95), which interacts with Fas-ligand to initiate apoptosis.
- The effector phase, activated by the binding of receptors and ligands of the induction phase, leads to the activation of caspases, cystinyl-aspartate-requiring proteinases (proteolytic enzymes), including
caspases 1 and 8. This activation may be associated with a change in the permeability of mitochondria, allowing the release of cytochrome-c which is involved in caspase activation. Activated caspases initiate a chain of lethal proteolytic events culminating in the changes in chromatin and cytoskeletal components seen in apoptosis. - Many cells undergoing apoptosis can be identified by a characteristic ‘laddering’ of DNA seen on agarose gel electrophoresis, resulting from cleavage of DNA into a series of fragments. These changes occur a few hours before death of the cell as defined by the ability of a cell to exclude vital dyes. The appearance of DNA laddering on agarose gel electrophoresis following extraction of DNA from cells is one recognised method of identification of apoptosis in cells [Loo, D. T. and Rillema, J. R. (1998) “Measurement of Cell Death,”Methods in Cell Biology 57: 251-264], although it is not always sensitive enough to detect apoptosis. In situ labelling of nuclear DNA fragmentation, for example, using commercially available terminal dUTP nick end labelling (TUNEL) assays, are an alternative and more reproducible measure for the determination of fragmented DNA in apoptotic cells and cells undergoing apoptosis [Gavrieli Y, Sherman Y, Ben-Sasson S A (1992)”, Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation”. Journal of Cell Biology 119: 493-501].
- During apoptosis, phosphatidylserine becomes exposed externally on the cell membrane [Fadok V A, Voelker D R, Campbell P A, Cohen J J, Bratton D L, Henson P M (1992), “Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages”. Journal of Immunology 148: 2207-2216] and this exposed phosphatidylserine binds to specific receptors to mediate the uptake and clearance of apoptotic cells in mammals [Fadok V A, Bratton D L, Rose D M, Pearson A, Ezekewitz R A B, Henson P M (2000), “A receptor for phosphatidylserine-specific clearance of apoptotic cells”, Nature 405: 85-90]. The surface expression of phosphatidylserine on cells is another recognised method of identification of apoptotic cells.
- Changes in mitochondrial integrity are intimately associated with apoptosis, resulting in alterations in mitochondrial membrane permeability and the release of cytochrome-c from the mitochondria into the cell cytoplasm [Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I, Brenner, C., Larochette, N., Prevost, M. C., Alzari, P. M. and Kroemer, G. (1999) “Mitochondrial Release of Caspase-2 and -9 during the Apoptotic Process”, Journal of Experimental Medicine, 189: 381 -394]. Measurement of changes in mitochondrial membrane potential, reflecting changes in mitochondrial membrane permeability, is another recognised method of identification of apoptotic cells.
- A number of other methods of identification of cells undergoing apoptosis and of apoptotic cells, many using monoclonal antibodies against specific markers for apoptotic cells, have also been described in the scientific literature.
- Necrosis, in contrast, is cell death of a pathological nature, resulting from injury, bacterial toxin effects, inflammatory mediators, etc., and involving membrane rupture and release of intracellular contents to the surrounding tissue, often with harmful inflammatory consequences. Accordingly, one of the ways in which necrotic cells may be detected and characterized is by detection of compromised cell membranes, e.g. by methods of staining with propidium iodide followed by flow cytometry or microscopy.
- This invention is directed, in part, to the novel and unexpected discovery that administration to a mammal of apoptotic cells and/or apoptotic bodies previously prepared ex vivo, can be used in the prophylaxis and/or treatment of neurodegenerative and/or other neurological disorders in the treated mammal.
- Accordingly, in one of its composition aspects, this invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable excipient and an effective amount of apoptotic cells and/or apoptotic bodies.
- The pharmaceutical compositions preferably employ an aqueous based pharmaceutically acceptable excipient although other excipients can be used.
- As noted above, these compositions are useful in the prophylaxis and/or treatment of neurodegenerative and/or other neurological disorders in mammals. Accordingly, in one of its method aspects, this invention is directed to a method for the treatment of or prophylaxis against neurodegenerative and other neurological medical disorders in a mammalian patierit, which comprises administering to the patient an effective amount of apoptotic bodies and/or apoptotic cells.
- These methods are preferably accomplished by administering to the patient the pharmaceutical compositions described herein.
- The FIGURE is a graph showing a comparison of net ear swelling in mice treated with the compositions of this invention and a control group.
- This invention is directed to the treatment and/or prophylaxis of neurodegenerative and/or other neurological disorders by the administration of apoptotic cells and/or bodies.
- Neurodegenerative disorders, including Down's syndrome, Alzheimer's disease and Parkinson's disease, are associated with increased levels of reactive oxygen species (ROS), certain inflammatory cytokines, including interleukin-1β (IL-1β) [see Griffin W S T, Stanley L C, Ling C, White L, Macleod V. Perrot L J, White C L, Araoz C (1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down's syndrome and Alzheimer disease. Proceedings of the National Academy of Sciences USA 867611-7615; Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996). Interleukin (IL)-1 beta, IL-1, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neuroscience Letters 211:13-16]. It has also been shown that IL-1β inhibits long-term potentiation in the hippocampus [Murray C A, Lynch M A (1998). Evidence that increase hippocampal expression of the cytokine interleukin-1β is a common trigger for age and stress-induced impairments in long-term potentiation. Journal of Neuroscience 18:2974-2981]. Long-term potentiation in the hippocampus is a form of synaptic plasticity and is generally considered to be an appropriate model for memory and learning [Bliss T V P, Collinridge G L, (1993). A synaptic model of memory: long-term potentiation in the hippocampus, Nature 361:31-39]. Thus, inappropriate cytokine expression in the brain is currently believed to be involved in the development and progression of neuroinflammatory diseases.
- Neurodegenerative and other neurological disorders treatable by the present invention include Down's syndrome, Alzheimer's disease, Parkinson's disease, senile dementia, depression and the like. In summary, it can be substantially any neurodegenerative or other neurological disorder.
- “Apoptotic cells” and “apoptotic bodies,” as the terms are used herein, means cells and cell bodies which exhibit one or more of the following apoptosis-characterizing features: surface exposure of phosphatidylserine, as detected by standard, accepted methods of detection such as Annexin V staining; alterations in mitochondrial membrane permeability measured by standard, accepted methods (e.g. Salvioli, S., Ardizzoni, A., Franceschi, C. Cossarizza, A. (1997) “JC-1, but not DiOC6(3) or Rhodamine 123, is a Reliable Fluorescent Probe to assess Delta Psi Changes in Intact Cells: Implications for Studies on Mitochondrial Functionality during Apoptosis,” FEBS Letters 411: 77-82]; evidence of DNA fragmentation such as the appearance of DNA laddering on agarose gel electrophoresis following extraction of DNA from the cells [Teiger, E., Dam, T. V., Richard, L., Wisnewsky, C., Tea, B. S., Gaboury, L., Tremblay, J., Schwartz, K. and Hamet, P. (1996) “Apoptosis in Pressure Overload-induced Heart Hypertrophy in the Rat,” Journal of Clinical Investigation 97; 2891-2897], or by in situ labeling (see Gavrieli et al., 1992, referenced above).
- The apoptotic cells and/or apoptotic bodies for use in the present invention preferably comprise not more than about 35 weight percent of necrotic cells and/or necrotic bodies based on the total weight of the apoptotic cells/bodies and necrotic cells/bodies; more preferably, not more than about 20 weight percent; and even more preferably, not more than about 10 weight percent. At these levels, the presence of such necrotic cells and/or bodies are believed not to significantly alter in vivo processes. In its most preferred embodiment, the apoptotic cells/bodies are substantially free of necrotic cells and or bodies (i.e., less than about 2 weight percent of necrotic cells/bodies).
- The apoptotic cells and/or apoptotic bodies for use in the present invention are prepared ex vivo from mammalian cells that are compatible with those of the mammalian patient. They can be prepared from substantially any type of mammalian cell including cultured cell lines. Preferably they are prepared from a cell type derived from the mammalian patient's own body or from an established cell line. More preferably they are prepared from white blood cells of blood compatible with that of the mammalian patient, more preferably from the patient's own white blood cell and even more preferably from the patient's own T lymphocytes. Even more preferably they are prepared from an established cell line. The apoptotic cells and/or apoptotic bodies are prepared extracorporeally prior to administration to the patient. Thus, in one embodiment, an aliquot of the patient's blood may be withdrawn, e.g. by venipuncture, and at least a portion of the white cells thereof subjected extracorporeally to apoptosis inducing conditions.
- A variety of methods of inducing apoptosis in mammalian cells, so as to create apoptotic cells and apoptotic bodies, are known in the art and essentially any of these can be adopted in preparing apoptotic bodies for use in the present invention. One such method is the subjection of the cells to ionizing radiation (Δ-rays, x-rays, etc.) and/or non-ionizing electromagnetic radiation including ultraviolet light. Apoptosis can be induced by subjecting cells to ultrasound.
- Another method is the treatment of the cells with drugs such as non-specific protein kinase inhibitors as exemplified by staurosporine (see Bombeli, Karsan, Tait and Hirlan, (1997) “Apoptotic Vascular Endothelial Cells Become Procoagulant”, Blood, Vol. 89:2429-2442). Also, certain chemotherapeutic agents used for the treatment of malignant tumours induce apoptosis, for example adriamycin, as can statin drugs (3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors) [Guijarro C, Blanco-Colio L M, Ortego M, Alonso C, Ortiz A, Plaza J J, Diaz C, Hernandez G, Edigo J (1998), “3-hydroxy-3methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle in culture,“Circulation Research 83: 490-500] and colcicine [Suzuki Y (1998)”, “Cell death, phagocytosis and neurogenesis in mouse olfactory epithelium and vomeronasal organ after colcicine treatment,” Annals of the New York Academy of Sciences 855: 252-254]. The use of ligands for death receptors on cells, such as Fas-ligand, will be apparent for inducing apoptosis from the discussion of apoptosis above.
- Yet another method is the application of oxidative stress to cells extracorporeally (see for example Buttke and Sandstrom (1994) “Oxidative Stress as a Mediator of Apoptosis,” Immunology Today, Vol. 15:7-10). This can be achieved by treating the cells, in suspension, with chemical oxidizing agents such as hydrogen peroxide, other peroxides and hydroperoxides, ozone, permanganates, periodates, and the like. Biologically acceptable such oxidizing agents are preferably used, so as to reduce potential problems associated with residues and contaminations of the apoptotic cells and apoptotic bodies so formed.
- The present invention is not restricted to any particular method of producing apoptotic cells and apoptotic bodies, for use herein, and any suitable, known process can be used.
- Methods for the detection and quantitation of apoptosis can be used to determine the presence and level of apoptosis in the preparation to be administered to the patient in the present invention. At least one of the methods from those described in the introduction above should be used to confirm the level of apoptosis achieved prior to administration. They are suitably purified prior to use, by methods known in the art, such as differential centrifugation.
- In preparing the apoptotic cells and/or apoptotic bodies, care should be taken not to apply excessive levels of oxidative stress, radiation, drug treatment, etc., since otherwise there is a significant risk of causing necrosis of at least some of the cells under treatment. Necrosis causes cell membrane rupture and the release of cellular contents often with biologically harmful results, particularly inflammatory events, so that the presence of necrotic cells and their components along with the apoptotic bodies is best avoided. Appropriate levels of treatment of the cells to create apoptotic bodies for use in the present invention depend to some extent on the nature of the chosen cells and cellular composition, and the type of treatment chosen to induce apoptosis. Such appropriate levels are readily determinable by those skilled in the art, having regard to the available scientific literature on the subject including the above-reference articles.
- One preferred process according to the present invention involves the culture of cells from the patient, or a compatible mammalian cell line. The cultured cells may then be treated to induce apoptosis and to create apoptotic cells and/or apoptotic bodies therein. The cells, suspended in the patient's plasma or another suitable suspension medium, such as saline or a balanced mammalian cell culture medium, can then be administered as indicated below. The numbers of apoptotic cells and/or bodies can be determined by published methods available in the scientific literature on the subject including the above-reference articles. The numbers of such apoptotic cells and/or apoptotic bodies required for administration to the patient to obtain the required clinical benefit will vary depending on the source of cells, the patient's condition, the age and weight of the patient and other relevant factors which are readily determinable by the attending clinician.
- Thus, an example of a preferred process according to the present invention accordingly involves extraction of an aliquot of blood from the patient to be treated, separation of the white cells therefrom, and treatment of the white cells under apoptosis-causing conditions, so as to create a cellular composition in which significant numbers of the white cells therein have been apoptosed so as to create therein substantial numbers of apoptotic cells or bodies. Then the treated composition is administered to the patient. More preferably, T lymphocytes, isolated from the blood by known means, and suspended as above, may be used as a source of apoptotic cells and apoptotic bodies.
- The number of viable cells selected for treatment to create apoptotic cells and/or apoptotic bodies is suitably up to about 4×109, preferably from about 1,000,000 to about 1,000,000,000 and most preferably from about 50,000,000 to about 150,000,000, for each administration to a human patient. From about 10% to 90%, preferably from about 30% to 70% of the cellular composition for administration is comprised of apoptotic bodies and/or apoptotic cells, the balance being viable cells and necrotic cells. Accordingly, the preferred amounts of apoptotic cells and/or apoptotic bodies for administration are those produced by subjecting these numbers of cells to the apoptosing conditions. When whole blood is used as the source of the cells to be subjected to the apoptosis inducing conditions, these numbers of white cells are obtainable in blood aliquots of volume up to about 400 ml, preferably up to 100 ml. More specifically, 50,000,000-150,000,000 cells is equivalent to the white cells in blood aliquots of volume 10 -30 ml.
- The volume of the aliquot of blood withdrawn from the patient for treatment to create apoptotic cells and/or apoptotic bodies therein is suitable up to about 400 ml, preferably from about 0.1 to about 100 ml and most preferably from about 5 to about 15 ml. Accordingly, the preferred amounts of apoptotic cells and/or apoptotic bodies for administration are those corresponding to the numbers derivable from the white blood cells, or isolated T lymphocytes, contained in such quantities of whole blood, following subjection to apoptosis-inducing conditions.
- The suspension of treated apoptotic cells and/or bodies for administration to the patient is prepared in a biologically acceptable liquid suspending medium, such as the patient's serum or plasma, saline or balanced mammalian cell culture medium. The addition of other factors, such as cytokines, hormones, products of stressed cells or other appropriate biologically active material may enhance the benefit of the administered apoptotic cellular materials. The aliquot can be introduced into the patient's body by any suitable method, most preferably intramuscular injection but also including subcutaneous injection, mini-grafting, intra peritoneal injection, intra-arterial injection, intravenous injection and oral administration. The apoptotic entities can be delivered to the specific body organ and/or site by using any appropriate, known delivery system.
- The compositions of this invention may optionally include a pharmaceutically acceptable excipient. Some examples of suitable excipients include sterile water, sterile saline, phosphate buffered saline, and the like.
- When administered, the pharmaceutical compositions comprise an effective amount of apoptotic bodies/cells to induce a suitable prophylactic and/or therapeutic response in the patient at risk of suffering or suffering from a neurodegenerative disease. Preferably, the composition administered to the mammalian patient comprises from about 10,000 to 10,000,000 apoptotic cells or bodies per kilogram of body weight, more preferably from about 500,000 to 5,000,000 and most preferably from about 1,500,000 to about 4,000,000 apoptotic cells and/or bodies per kg body weight. The specific dose employed will, of course, be dependent upon the age, weight and severity of the disease in the treated patient all of which are within the skill of the attending clinician.
- For most effective treatment and/or prophylaxis of mammalian disorders involving a neurodegenerative or neurological disorder, the patient may be given a course of treatments with apoptotic cells and/or bodies according to the invention. Each course of treatment may involve administration to the patient of from 1 to 6 aliquots of suspended cellular material, as described above. No more than one such aliquot should be administered per day, and the maximum rest period between any two consecutive administrations should be not greater than about 21 days. Booster treatments as described below may advantageously be used. To maintain the desired effects, the patient may undergo booster treatments, with a further course of administration of aliquots of suspended apoptotic cells and/or apoptotic bodies as described above, at intervals of three to four months.
- As noted, the present invention is applicable to the treatment and prophylaxis of a wide variety of mammalian neurodegenerative and other neurological disorders. These include, but are not limited to, Down's Syndrome, Alzheimer's disease, Parkinson's disease, senile dementia, depression, multiple sclerosis, Huntington's disease, peripheral neuropathies, spinal cord diseases, neuropathic joint diseases, chronic inflammatory demyelinating disease (CIPD), neuropathies including mononeuropathy, polyneuropathy, symmetrical distal sensory neruopathy, cystic fibrosis, neuromuscular junction disorders and myasthenias. In summary, it can be substantially any neurodegenerative or other neurological disorder.
- The invention is further described, for illustrative purposes, in the following specific examples.
- Experiments to demonstrate the invention were conducted on laboratory mice, under approved conditions for conducting such experiments.
- The effectiveness of the treatment according to a preferred embodiment of the present invention, on contact hypersensitivity (CHS), an example of a Th-1-cell inflammatory disorder which is known to be mediated by inflammatory cytokines, was assessed on laboratory mice, according to approved animal experimentation procedures, using the method described by Kondo et. al., “Lymphocyte function associated antigen-1 (LFA-1) is required for maximum elicitation of allergic contact dematitis” Br. J. Dermatol. 131:354-359 (1994), with minor variations. The disclosure thereof is incorporated herein by reference. Briefly, to induce C H S, the abdominal skin of each mouse was shaved and painted with dinitrodifluorobenzene DNFB, the sensitizing chemical, using 25 μl of 0.5% DNFB in 4:1 acetone:olive oil solution. This sensitization was applied to two groups of Balb/c mice, 10 animals in total.
- Apoptotic bodies were prepared from murine fibroblasts. The murine fibroblasts were treated with 50 mM sodium butyrate in RPMI medium, at confluency for one day, and then the sodium butyrate medium was changed. To increase the number of apoptotic cells and bodies, the cells can additionally be irradiated with UV-light.(e.g. 75 mj). Supernatant containing floating cells is removed 24 hours following irradiation.
- Apoptotic bodies were quantitated by centrifuging the supernatant (1200 rpm, 5 minutes), aspirating the supernatant, washing the resulting cell pellet with PBS and centrifuging again, as above. The pellet containing the apoptotic bodies was re-suspended in PBS. The cells were stored in PBS at 4° C. for the duration of the experiment. The cells to be stained for quantitation were re-suspended in 1X binding buffer at a concentration of 1×106 cells/ml. 100 μl of the cells were transferred to a 5 m1 tube, and 10 μl of fluorescein-conjugated annexin V and 10 μl propidium iodide reagent was added. The cells were gently vortexed and the cell mixture incubated for 15 minutes at 25° C. in the dark. Following the incubation, 400 μl of 1X binding buffer is added to each tube. The sample was analyzed on a flow cytometer over one hour.
- Of the two groups of sensitized mice, the first, control group A, received no treatment. The second, test group B, was treated with an injection of suspended apoptotic bodies prepared as described above, 50 μl volume containing at least 150,000 bodies per injection of blood subjected to stressors as described above. Treatments, each involving intramuscular injection of 50 μl of the respective liquid, started on the day of sensitization, and were repeated every day for a total of six days. On the same day as the last treatment, but after its administration, the animals were challenged with DNFB, by applying to the right ear of each animal 10μl of 0.2% solution of DNFB in acetone and olive oil. To the left ear of each animal was applied the acetone/olive oil solvent, without DNFB. Inflammation due to CHS manifests itself in a swelling of the right ears. Ear thickness was measured, 24 hours after challenge, with a Peacock spring-loaded micrometer (Ozaki Co., Tokyo, Japan). The results were expressed as the thickness and difference in thickness of the right ears and the left ears of each animal, at 24 hours after challenge.
- The experiments were repeated, using more sets of two groups of animals, a sufficient number of times to ensure statistical significance in the results. A notable and significant reduction in ear thickness (inflammation) was observed with the animals treated with the apoptotic cells and apoptotic bodies suspension in accordance with the invention, as compared with the untreated group, demonstrating a significant reduction in inflammation. The results are presented in the following Table, and on the accompanying Figure, as a bar graph of net ear swelling (difference between right ear and left ear thickness), for each group, with “standard deviation” shown by the vertical line at the top of each column.
TABLE 1 Group Left ear Right ear Difference A 17 31 14 A 18 39 21 A 17 30 13 A 18 32 14 A 18 31 13 Mean: 15 S.D: 3.391165 B 21 31 10 B 18 18 0 B 17 30 13 B 20 24 4 B 18 22 4 Mean: 6.2 S.D.: 5.215362 - An analysis of the suspension of apoptotic cells and bodies administered to the animals of test group B indicated the presence therein of approximately 40% apoptotic cells and bodies, balance viable cells and minor amounts of necrotic cells (not more than 20%), the presence of which is believed to be insignificant in the in vivo process.
- The above test procedure was repeated on similar groups of animals, a control group and a test group, but using a suspension of apoptotic cells and bodies on the test group which comprised about 60% apoptotic cells and bodies, balance viable cells and a minor amount (not more than 20%) of necrotic cells. Essentially similar results were obtained.
- The effectiveness of the processes and compositions of the present invention in preventing and alleviating inflammation due to CHS indicates that administration of apoptotic cells and bodies as described up-regulates the in vivo generation of anti-inflammatory Th-2 derived cytokines such as IL-10 (known to be implicated in CHS—see Kondo, McKenzie and Sauder, “The Journal of Investigative Dermatology,” Vol. 103, 1994, page 811-814) and/or down-regulates Th-1 inflammatory cytokines such as TNFα and IL-6. These inflammatory cytokines are implicated in inflammation-related disorders of the brain, namely the neuroinflammatory, neurodegenerative and neurological disorders such as Alzheimer's disease, senile dementia, multiple sclerosis, depression, Down's syndrome, Huntington's disease, peripheral neuropathies, spinal cord diseases, neuropathic joint diseases, chronic inflammatory demyelinating disease (CIPD), neuropathies including mononeuropathy, polyneuropathy, symmetrical distal sensory neuropathy, cystic fibrosis, neuromuscular junction disorders, myasthenias and Parkinson's disease.
- Neurodegenerative diseases, including Down's syndrome, Alzheimer's disease and Parkinson's disease, are associated with increased levels of certain inflammatory cytokines, including interleukin-1β (IL-1β) [see Griffin W S T, Stanley L C, Ling C, White L, Macleod V. Perrot L J, White C L, Araoz C (1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proceedings of the National Academy of Sciences USA 867611-7615; Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996). Interleukin (IL)-1 beta, IL-1, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neuroscience Letters 211:13-16]. It has also been shown that IL-1β, inhibits long-term potentiation in the hippocampus [Murray C A, Lynch M A (1998). Evidence that increase hippocampal expression of the cytokine interleukin-1β is a common trigger for age and stress-induced impairments in long-term potentiation. Journal of Neuroscience 18:2974-2981]. Long-term potentiation in the hippocampus is a form of synaptic plasticity and is generally considered to be an appropriate model for memory and learning [Bliss T V P, Collinridge G L, (1993). A synaptic model of memory: long-term potentiation in the hippocampus, Nature 361:31-39]. Thus, inappropriate cytokine expression in the brain is currently believed to be involved in the development and progression of neurodegenerative diseases. Consequently, the finding of success in CHS treatment reported in the above Examples, with its attendant down-regulation of Th-1 inflammatory cytokines, is indicative of successful use of the process and compositions in the treatment and prophylaxis of a wide variety of neurological disorders including those discussed above.
Claims (19)
1. The use of apoptotic bodies and/or apoptotic cells in treatment and/or prophylaxis in mammalian patients of neurodegenerative and other neurological medical disorders.
2. The use of apoptotic bodies and/or apoptotic cells in the preparation of a medicament for the treatment and/or prophylaxis of neurodegenerative and other neurological medical disorders in mammalian patients.
3. The use of claim 2 wherein apoptotic bodies and/or apoptotic cells are in a liquid suspension along with viable cells.
4. The use of claim 3 wherein the apoptotic bodies and/or apoptotic cells comprise from 10% to 90% of the cellular portion of the suspension.
5. The use of claim 4 wherein the apoptotic bodies and/or apoptotic cells comprise from 30% to 70% of the cellular portion of the suspension.
6. The use of claim 1 or 2 wherein the apoptotic bodies and/or cells are derived from extracorporeal treatment of blood cells compatible with those of the mammalian patient.
7. The use of claim 1 or 2 wherein the apoptotic bodies and/or cells are derived from established cultured cell lines.
8. The use of claim 6 wherein the blood cells are white blood cells of blood compatible with that of the mammalian patient.
9. The use of claim 8 wherein the blood cells are the patient's own white blood cells.
10. The use of claim 9 wherein the blood cells are the patient's own T lymphocytes.
11. The use of claim 1 or 2 wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, multiple sclerosis, depression, Down's syndrome, Huntington's disease, peripheral neuropathies, spinal cord diseases, neuropathic joint diseases, chronic inflammatory demyelinating disease (CIPD), neuropathies including mononeuropathy, polyneuropathy, symmetrical distal sensory neuropathy, cystic fibrosis, neuromuscular junction disorders, myasthenias and Parkinson's disease.
12. The use of claim 1 or 2 further comprising administering to a human patient a dosage of apoptotic bodies and/or apoptotic cells comprising from 10,000 to 10,000,000 apoptotic bodies and/or apoptotic cells per kilogram body weight of the patient.
13. The use of claim 12 wherein the dosage contains from 500,000 to 5,000,000 apoptotic bodies and/or apoptotic cells per kilogram body weight of the patient.
14. The use of claim 12 wherein the dosage contains from 1,500,000 to 4,000,000 apoptotic bodies and/or apoptotic cells per kilogram body weight of the patient.
15. A method for treatment of or prophylaxis against T-cell-mediated and inflammatory disorders in a mammalian patient, which comprises administering to the patient an effective amount of apoptotic bodies and/or apoptotic cells.
16. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and an effective amount of apoptotic bodies and/or apoptotic cells.
17. The pharmaceutical composition of claim 16 which is suitable for administration to a mammalian patient to treat or to effect prophylaxis against neurodegenerative and other neurological medical disorders.
18. The composition of claim 16 or 17 comprising a liquid suspension of cellular material, from 10% to 90% of the cellular material being apoptotic bodies and/or apoptotic cells.
19. A unit dosage composition for administration to a human patient for alleviation or prophylaxis of a nuerological or neurodegenerative disorder, comprising a liquid suspension of cellular material including from about 10,000 to 10,000,000 apoptotic cells and/or apoptotic bodies per kilogram of patient body weight.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/583,986 US20070087010A1 (en) | 2000-05-25 | 2006-10-17 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
US11/927,094 US20080131416A1 (en) | 2000-05-25 | 2007-10-29 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2309424 CA2309424A1 (en) | 2000-05-25 | 2000-05-25 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
CA2,309,424 | 2000-05-25 | ||
US09/871,146 US7132285B2 (en) | 2000-05-25 | 2001-05-25 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
US11/583,986 US20070087010A1 (en) | 2000-05-25 | 2006-10-17 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/871,146 Division US7132285B2 (en) | 2000-05-25 | 2001-05-25 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/927,094 Continuation US20080131416A1 (en) | 2000-05-25 | 2007-10-29 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070087010A1 true US20070087010A1 (en) | 2007-04-19 |
Family
ID=4166243
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/871,146 Expired - Fee Related US7132285B2 (en) | 2000-05-25 | 2001-05-25 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
US11/583,986 Abandoned US20070087010A1 (en) | 2000-05-25 | 2006-10-17 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
US11/927,094 Abandoned US20080131416A1 (en) | 2000-05-25 | 2007-10-29 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/871,146 Expired - Fee Related US7132285B2 (en) | 2000-05-25 | 2001-05-25 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/927,094 Abandoned US20080131416A1 (en) | 2000-05-25 | 2007-10-29 | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
Country Status (13)
Country | Link |
---|---|
US (3) | US7132285B2 (en) |
EP (1) | EP1289535B1 (en) |
JP (1) | JP2003534282A (en) |
AT (1) | ATE366581T1 (en) |
AU (1) | AU2001261987A1 (en) |
CA (1) | CA2309424A1 (en) |
DE (1) | DE60129322T2 (en) |
DK (1) | DK1289535T3 (en) |
ES (1) | ES2290134T3 (en) |
HK (1) | HK1055080A1 (en) |
PT (1) | PT1289535E (en) |
TW (1) | TWI239843B (en) |
WO (1) | WO2001089537A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070224256A1 (en) * | 2000-09-18 | 2007-09-27 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2309518A1 (en) * | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
CA2333494A1 (en) * | 2001-02-01 | 2002-08-01 | Vasogen Ireland Limited | Blood brain barrier modulation |
EP1429727A1 (en) * | 2001-09-18 | 2004-06-23 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
US20060008517A1 (en) * | 2004-07-09 | 2006-01-12 | Lynch Marina A | Treatment of age-related memory impairment |
WO2016132366A1 (en) | 2015-02-18 | 2016-08-25 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US10857181B2 (en) | 2015-04-21 | 2020-12-08 | Enlivex Therapeutics Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
KR20180110141A (en) | 2016-02-18 | 2018-10-08 | 엔리벡스 테라퓨틱스 리미티드 | Combination of immunotherapy and cytokine regulating therapy to treat cancer |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5980954A (en) * | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
US20020051771A1 (en) * | 2000-05-25 | 2002-05-02 | Bolton Anthony E. | Apoptotic entities for use in treatment of T-cell-mediated and inflammatory disorders |
US20020058023A1 (en) * | 2000-05-25 | 2002-05-16 | Bolton Anthony E. | Apoptotic entities for use in treatment of endothelium dysfunction disorders |
US20030139466A1 (en) * | 2001-11-29 | 2003-07-24 | Peritt David L. | Methods for pretreating a subject with extracorporeal photopheresis |
US6696092B2 (en) * | 1992-02-07 | 2004-02-24 | Vasogen Ireland Limited | Endothelial lining effects and treatment of vasospastic disorders |
US6986888B1 (en) * | 1999-05-06 | 2006-01-17 | Vasogen Ireland Limited | Method for treating mammals with modified mammalian blood |
US7122208B2 (en) * | 2001-04-06 | 2006-10-17 | Vasogen Ireland Limited | Compositions containing apoptotic entities |
US7255880B2 (en) * | 2003-04-03 | 2007-08-14 | Vasogen Ireland Limited | Treatment of endothelin-related disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE350046T1 (en) * | 1992-02-07 | 2007-01-15 | Vasogen Ireland Ltd | USE OF BLOOD WITH INCREASED NITROGEN OXIDE CONCENTRATION TO PRODUCE A MEDICATION |
EP1146885B1 (en) | 1999-01-12 | 2003-05-28 | Centre De Recherche Du Centre Hospitalier De L'Universite De Montreal | Pre-conditioning against cell death |
PT1261785E (en) | 2000-03-07 | 2003-10-31 | E F P Floor Products Fussboden | SPACE PANEL PAVING PANEL |
-
2000
- 2000-05-25 CA CA 2309424 patent/CA2309424A1/en not_active Abandoned
-
2001
- 2001-05-25 EP EP20010935897 patent/EP1289535B1/en not_active Expired - Lifetime
- 2001-05-25 DK DK01935897T patent/DK1289535T3/en active
- 2001-05-25 WO PCT/CA2001/000759 patent/WO2001089537A2/en active IP Right Grant
- 2001-05-25 AT AT01935897T patent/ATE366581T1/en not_active IP Right Cessation
- 2001-05-25 PT PT01935897T patent/PT1289535E/en unknown
- 2001-05-25 ES ES01935897T patent/ES2290134T3/en not_active Expired - Lifetime
- 2001-05-25 DE DE2001629322 patent/DE60129322T2/en not_active Expired - Fee Related
- 2001-05-25 US US09/871,146 patent/US7132285B2/en not_active Expired - Fee Related
- 2001-05-25 JP JP2001585781A patent/JP2003534282A/en not_active Withdrawn
- 2001-05-25 AU AU2001261987A patent/AU2001261987A1/en not_active Abandoned
- 2001-06-01 TW TW90113346A patent/TWI239843B/en not_active IP Right Cessation
-
2003
- 2003-09-10 HK HK03106461A patent/HK1055080A1/en not_active IP Right Cessation
-
2006
- 2006-10-17 US US11/583,986 patent/US20070087010A1/en not_active Abandoned
-
2007
- 2007-10-29 US US11/927,094 patent/US20080131416A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5980954A (en) * | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
US6696092B2 (en) * | 1992-02-07 | 2004-02-24 | Vasogen Ireland Limited | Endothelial lining effects and treatment of vasospastic disorders |
US6986888B1 (en) * | 1999-05-06 | 2006-01-17 | Vasogen Ireland Limited | Method for treating mammals with modified mammalian blood |
US20020051771A1 (en) * | 2000-05-25 | 2002-05-02 | Bolton Anthony E. | Apoptotic entities for use in treatment of T-cell-mediated and inflammatory disorders |
US20020058023A1 (en) * | 2000-05-25 | 2002-05-16 | Bolton Anthony E. | Apoptotic entities for use in treatment of endothelium dysfunction disorders |
US7279156B2 (en) * | 2000-05-25 | 2007-10-09 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of endothelium dysfunction disorders |
US7122208B2 (en) * | 2001-04-06 | 2006-10-17 | Vasogen Ireland Limited | Compositions containing apoptotic entities |
US20030139466A1 (en) * | 2001-11-29 | 2003-07-24 | Peritt David L. | Methods for pretreating a subject with extracorporeal photopheresis |
US20030157073A1 (en) * | 2001-11-29 | 2003-08-21 | Peritt David L. | Methods for pretreating a subject with apoptotic cells |
US7255880B2 (en) * | 2003-04-03 | 2007-08-14 | Vasogen Ireland Limited | Treatment of endothelin-related disorders |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070224256A1 (en) * | 2000-09-18 | 2007-09-27 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
US7597906B2 (en) * | 2000-09-18 | 2009-10-06 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
Also Published As
Publication number | Publication date |
---|---|
ATE366581T1 (en) | 2007-08-15 |
WO2001089537A2 (en) | 2001-11-29 |
US20020044924A1 (en) | 2002-04-18 |
US7132285B2 (en) | 2006-11-07 |
US20080131416A1 (en) | 2008-06-05 |
DE60129322T2 (en) | 2008-03-13 |
DK1289535T3 (en) | 2007-11-05 |
PT1289535E (en) | 2007-10-19 |
JP2003534282A (en) | 2003-11-18 |
CA2309424A1 (en) | 2001-11-25 |
EP1289535B1 (en) | 2007-07-11 |
AU2001261987A1 (en) | 2001-12-03 |
WO2001089537A3 (en) | 2002-08-01 |
TWI239843B (en) | 2005-09-21 |
EP1289535A2 (en) | 2003-03-12 |
HK1055080A1 (en) | 2003-12-24 |
ES2290134T3 (en) | 2008-02-16 |
DE60129322D1 (en) | 2007-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070087010A1 (en) | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders | |
EP1289534B1 (en) | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders | |
de Souza et al. | Blockade by antimacrophage serum of the migration of PMN neutrophils into the inflamed peritoneal cavity | |
Farsky et al. | Leukocyte response induced by Bothrops jararaca crude venom: in vivo and in vitro studies | |
EP1176972A1 (en) | Use of phyllanthus for targeted stimulation of the immune system | |
US20080063631A1 (en) | Apoptotic entities for use in treatment of endothelium dysfunction disorders | |
de Oliveira et al. | Developments on drug discovery and on new therapeutics: highly diluted tinctures act as biological response modifiers | |
Sakti et al. | Phagocytosis Activity of binahong (anredera cordifolia (tenore.) steenis) from secang, magelang, central java, Indonesia | |
Han et al. | Activation of murine macrophage cell line RAW 264.7 by Korean propolis | |
CA2409992A1 (en) | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders | |
CA2409960A1 (en) | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders | |
US20070298020A1 (en) | Apoptotic entities for use in treatment of endothelium dysfunction disorders | |
CA2409994A1 (en) | Apoptotic entities for use in treatment of endothelium dysfunction disorders | |
Sandbank et al. | Mitochondrial changes in the guinea-pig muscle after envenomation with Vespa orientalis venom | |
Chen et al. | Novel Application of Immunomodulatory Mushroom Polysaccharide (β-Glucan) and Triterpenes for Diabetic Wound Care | |
US20020114846A1 (en) | Amniotic apoptosis modulating substances | |
Singh et al. | Immunomodulatory and anti-tumor actions of Tinospora cordifolia (Guduchi) | |
EP0889053A2 (en) | Uses of BK-RiV preparations, process for their production and proteins comprised therein | |
WO2002004516A2 (en) | Use of the heat shock protein gp96 | |
KIRUTHIKA et al. | IN VITRO ANTI-INFLAMMATORY ACTIVITY OF METHANOL EXTRACT OF PEDALIUM MUREX |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VASOGEN IRELAND LIMITED, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOLTON, ANTHONY E;MANDEL, ARKADY;SAUDER, DANIEL;REEL/FRAME:018754/0478;SIGNING DATES FROM 20011101 TO 20011102 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |